<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="14215"><DrugName>SR-144190</DrugName><DrugSynonyms><Name><Value>SR-144190</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>201152-86-5</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="26494">Sanofi-Synthelabo</CompanyOriginator><CompaniesSecondary><Company id="26494">Sanofi-Synthelabo</Company><Company id="26495">Sanofi (pre-1999)</Company><Company id="26658">Sanofi Recherche SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="14215" type="Drug"><TargetEntity id="256855" type="siDrug">SR-144190</TargetEntity></SourceEntity><SourceEntity id="26494" type="Company"><TargetEntity id="5000326934" type="organizationId">Sanofi Synthelabo Caraibes SARL</TargetEntity></SourceEntity><SourceEntity id="26495" type="Company"><TargetEntity id="4295866846" type="organizationId">Thales SA</TargetEntity></SourceEntity><SourceEntity id="26658" type="Company"><TargetEntity id="5035524034" type="organizationId">Sanofi Recherche SA</TargetEntity></SourceEntity><SourceEntity id="187" type="ciIndication"><TargetEntity id="10046543" type="MEDDRA"></TargetEntity><TargetEntity id="D014549" type="MeSH"></TargetEntity><TargetEntity id="-1859456438" type="omicsDisease"></TargetEntity><TargetEntity id="355" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="192" type="ciIndication"><TargetEntity id="K58" type="ICD10"></TargetEntity><TargetEntity id="10023003" type="MEDDRA"></TargetEntity><TargetEntity id="D043183" type="MeSH"></TargetEntity><TargetEntity id="-716973018" type="omicsDisease"></TargetEntity><TargetEntity id="397" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="25" type="ciIndication"><TargetEntity id="10057666" type="MEDDRA"></TargetEntity><TargetEntity id="D001008" type="MeSH"></TargetEntity><TargetEntity id="-1384065283" type="omicsDisease"></TargetEntity><TargetEntity id="30" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="60" type="ciIndication"><TargetEntity id="D002493" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"></TargetEntity><TargetEntity id="D003863" type="MeSH"></TargetEntity><TargetEntity id="-508468160" type="omicsDisease"></TargetEntity><TargetEntity id="53" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="267" type="Action"><TargetEntity id="317" type="Mechanism">Tachykinin NK2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-01433" type="ciTarget"><TargetEntity id="42129332968653" type="siTarget">Substance-K receptor</TargetEntity><TargetEntity id="-292574261" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="187">Urinary incontinence</Indication><Indication id="192">Irritable bowel syndrome</Indication><Indication id="20">Pain</Indication><Indication id="25">Anxiety disorder</Indication><Indication id="31">Asthma</Indication><Indication id="60">Central nervous system disease</Indication><Indication id="93">Depression</Indication></IndicationsSecondary><ActionsPrimary><Action id="267">NK2 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2941">Antidepressant</Action><Action id="2942">Anxiolytic</Action><Action id="2946">Analgesic</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>G4B4</Code><Name>Urinary incontinence products</Name></Ephmra><Ephmra><Code>N5C</Code><Name>TRANQUILLISERS</Name></Ephmra><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra><Ephmra><Code>N</Code><Name>CENTRAL NERVOUS SYSTEM</Name></Ephmra></EphmraCodes><LastModificationDate>2017-12-01T14:59:12.000Z</LastModificationDate><ChangeDateLast>2004-03-24T23:48:07.000Z</ChangeDateLast><AddedDate>1996-12-19T16:00:23.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="26494" linkType="Company"&gt;Sanofi-Synthelabo&lt;/ulink&gt; (formerly &lt;ulink linkID="26495" linkType="Company"&gt;Sanofi&lt;/ulink&gt;) was developing SR-144190, a neurokinin NK2 antagonist, as a potential treatment for CNS indications [&lt;ulink linkID="367094" linkType="reference"&gt;367094&lt;/ulink&gt;]. It had reached phase I trials for anxiety and depression by September 2001 [&lt;ulink linkID="421268" linkType="reference"&gt;421268&lt;/ulink&gt;], [&lt;ulink linkID="463211" linkType="reference"&gt;463211&lt;/ulink&gt;]; however, development of the compound had been discontinued by February 2003 [&lt;ulink linkID="479170" linkType="reference"&gt;479170&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The compound had also been under investigation as a potential oral treatment for asthma, incontinence [&lt;ulink linkID="330073" linkType="reference"&gt;330073&lt;/ulink&gt;], [&lt;ulink linkID="359231" linkType="reference"&gt;359231&lt;/ulink&gt;] and irritable bowel disorder and was thought to have potential as a cough suppressant and antidiarrheal [&lt;ulink linkID="227792" linkType="reference"&gt;227792&lt;/ulink&gt;], but these indications had been dropped by May 2000 [&lt;ulink linkID="367094" linkType="reference"&gt;367094&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; SR-144190 displayed similar potency at the human, rat and guinea pig receptors [&lt;ulink linkID="227792" linkType="reference"&gt;227792&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 1999, Lehman Brothers predicted a 5% chance that the compound would reach the market, with a potential launch anticipated in 2006 and potential peak sales of $200 million in 2014 [&lt;ulink linkID="346267" linkType="reference"&gt;346267&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="25">Anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-02-19T00:00:00.000Z</StatusDate><Source id="479170" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26658">Sanofi Recherche SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="192">Irritable bowel syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-05-19T00:00:00.000Z</StatusDate><Source id="367094" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-05-19T00:00:00.000Z</StatusDate><Source id="367094" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-09-07T00:00:00.000Z</StatusDate><Source id="421268" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-02-19T00:00:00.000Z</StatusDate><Source id="479170" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="187">Urinary incontinence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-05-19T00:00:00.000Z</StatusDate><Source id="367094" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-09-07T00:00:00.000Z</StatusDate><Source id="421268" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-09-07T00:00:00.000Z</StatusDate><Source id="421268" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-12-19T00:00:00.000Z</StatusDate><Source id="227792" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-12-19T00:00:00.000Z</StatusDate><Source id="227792" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="187">Urinary incontinence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-06-01T00:00:00.000Z</StatusDate><Source id="330073" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="60">Central nervous system disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-05-19T00:00:00.000Z</StatusDate><Source id="367094" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26495">Sanofi (pre-1999)</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="187">Urinary incontinence</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-06-01T00:00:00.000Z</StatusDate><Source id="330073" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26658">Sanofi Recherche SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-12-19T00:00:00.000Z</StatusDate><Source id="227792" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26658">Sanofi Recherche SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="192">Irritable bowel syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-12-19T00:00:00.000Z</StatusDate><Source id="227792" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26658">Sanofi Recherche SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1996-12-19T00:00:00.000Z</StatusDate><Source id="227792" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01433"><Name>NK2 receptor</Name><SwissprotNumbers><Swissprot>P05363</Swissprot><Swissprot>P16610</Swissprot><Swissprot>P21452</Swissprot><Swissprot>P30549</Swissprot><Swissprot>P51144</Swissprot><Swissprot>P79218</Swissprot><Swissprot>Q5DUB2</Swissprot><Swissprot>Q64077</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CN(C)C(=O)NC1(CCN(CC1)CC[C@]2(CN(CCO2)C(=O)c3ccccc3)c4ccc(c(c4)F)F)c5ccccc5</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="1751854" number="WO-00104105" title="Method for preparing 2-(2-arylmorpholin-2-yl)ethanol derivatives and intermediates"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Panasonic Corp" id="21309"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>